Abstract: The invention provides compositions and methods for delivering carbon monoxide (CO) to subjects suffering from inflammatory, cardiovascular, Sickle Cell, and other disease. The compositions are liquids, including Newtonian and non-Newtonian liquids, such as pastes, gels, foams, emulsions, and other non-gaseous compositions, in which CO is dissolved at an amount that, when administered to a patient, provides a therapeutically or prophylactically effective amount of CO to the patient. The compositions can be provided in many forms, including in bottles or cans.

Abstract: A novel free-breathing myocardial T2* mapping combining multiple single-shot black-blood GRE-EPI images with automatic non-rigid motion correction. The present disclosure describes a method of accurate myocardial T2* measurements that is insensitive to respiratory motion, and is likely to reduce sensitivity to arrhythmia as well since each image is acquired in a single heart beat. The T2*-weighted GRE-EPI images are motion corrected using, e.g., automatic non-rigid motion correction to reduce mis-registration due to respiratory motion. A T2* map is calculated using the motion-corrected T2*-weighted images by fitting pixel intensities to a, e.g., two-parameter mono-exponential model.

Abstract: A medical image processing apparatus according to the embodiments includes a display, and processing circuitry configured to execute a program. The processing circuitry extracts at least part of a lung from three-dimensional image data, extracts a tubular structure from at least part of the extracted lung, calculates area ratios between a lumen and a wall of the extracted tubular structure along the tubular structure, and generates area ratio images by allocating pixel values, corresponding to the calculated area ratios, to corresponding positions on the tubular structure having the area ratios being calculated, and displays the area ratio images on the display.

Abstract: The present invention provides novel ruthenium compounds of Formula (I): or salts, isomers, hydrates, or solvates thereof, or combinations thereof; wherein E, R1, R2, R3, R4, R5, X1, and X2 are as defined herein, and pharmaceutical compositions thereof. Also provided are methods of use and treatment. Such compounds have been found useful in the treatment of malaria infection. Such compounds may also be useful in the treatment of inflammatory conditions, such as acute lung injury and acute respiratory distress syndrome, which optionally may be associated with a malaria infection.

Abstract: Several classes of in vivo carbon monoxide-releasing compounds are useful for the treatment and/or prevention of diseases, such as chronic inflammatory, e.g., rheumatoid arthritis, and of diseases with a strong inflammatory component, such as atherosclerosis, stroke, coronary disease, and Alzheimers disease. The in vivo carbon monoxide-releasing compounds can be attached to known drug vectors and/or known anti-inflammatory drugs, such as aspirin.

Abstract: The present invention relates to a method of treating or preventing compartment syndrome in a patient. According to the invention, the method includes: (a) identifying a patient suffering from compartment syndrome; and (b) administering to the patient a therapeutically effective amount of a carbon monoxide (CO).

Abstract: The present invention is directed to dosing regimens for the administration of carbon monoxide in the treatment of various indications as well as methods for enhancing organ function following transplant thereof.

Abstract: The present invention relates to methods and compositions of treating patients suffering from, or at risk for, DNA damage and to increase life span, i.e., prevent or slow the aging process in all species. The treatment includes administering to the patient a pharmaceutical composition that includes carbon monoxide.

Abstract: The present invention provides novel ruthenium compounds of Formula (I): or salts, isomers, hydrates, or solvates thereof, or combinations thereof; wherein E, R1, R2, R3, R4, R5, X1, and X2 are as defined herein, and pharmaceutical compositions thereof. Also provided are methods of use and treatment. Such compounds have been found useful in the treatment of malaria infection. Such compounds may also be useful in the treatment of inflammatory conditions, such as acute lung injury and acute respiratory distress syndrome, which optionally may be associated with a malaria infection.

Abstract: The invention relates to the use of carbon monoxide (CO) to inhibit the gastrointestinal side effects caused by non-steroidal anti-inflammatory drugs (NSAIDs) and/or alcohol.

Abstract: The present invention is directed to dosing regimens for the administration of carbon monoxide in the treatment of various indications as well as methods for enhancing organ function following transplant thereof.

Abstract: The present invention relates to a method of treating hepatitis in a patient, which includes administering a pharmaceutical composition that includes carbon monoxide to the patient.

Abstract: The invention is directed to methods for diagnosing reperfusion/non-reperfusion hemorrhage and predicting cardiac arrhythmias and sudden cardiac death in subjects comprising using imaging techniques to detect regional iron oxide deposition. The invention also provides treatment methods for subject at increased risk of sudden cardiac death.

Abstract: An object of the present invention is to provide a composition for inhibiting fatty acid and cholesterol uptake in a living cell which is an inhibitor for fatty acid or cholesterol uptake by a living cell, comprising carbon monoxide (CO) or a compound capable of releasing CO in vivo.

Abstract: The invention provides compositions and methods for delivering carbon monoxide (CO) to subjects suffering from inflammatory, cardiovascular, Sickle Cell, and other disease. The compositions are liquids, including Newtonian and non-Newtonian liquids, such as pastes, gels, foams, emulsions, and other non-gaseous compositions, in which CO is dissolved at an amount that, when administered to a patient, provides a therapeutically or prophylactically effective amount of CO to the patient. The compositions can be provided in many forms, including in bottles or cans.

Abstract: The invention to provide a carbon dioxide mist pressure bath system which is possible to cause the carbon dioxide mist to be absorbed efficiently through the skin and mucous membrane of the human living-body. The system comprises a carbon dioxide supply means 11; a liquid supply means 21; a carbon dioxide mist generating means 31 for pulverizing and dissolving carbon dioxide and the liquid to generate the carbon dioxide mist; a living-body cover member 41 for covering the skin and mucous membrane of the living-body and formed with a space of sealing inside the carbon dioxide mist generated by the carbon dioxide mist generating means 31; and a liquid circulation means 61 for again supplying a liquid collected in the carbon dioxide mist generating means 31 into the carbon dioxide mist generating means.

Abstract: The invention to provide a carbon dioxide mist pressure bath system which is possible to cause the carbon dioxide mist to be absorbed efficiently through the skin and mucous membrane of the human living-body. The system comprises a carbon dioxide supply means 11; a liquid supply means 21; a carbon dioxide mist generating means 31 for pulverizing and dissolving carbon dioxide and the liquid to generate the carbon dioxide mist; a living-body cover member 41 for covering the skin and mucous membrane of the living-body and formed with a space of sealing inside the carbon dioxide mist generated by the carbon dioxide mist generating means 31; a liquid circulation means 61 for again supplying a liquid collected in the carbon dioxide mist generating means 31 into the carbon dioxide mist generating means; and a pressurization means 81 for pressurizing the inside of the living-body cover member 41.

Abstract: The present invention relates to a method of treating hepatitis in a patient, which includes administering a pharmaceutical composition that includes carbon monoxide to the patient.

Abstract: 1,5-octadien-3-ol is an attractant for biting insects, particularly mosquitoes and may be used alone or with other attractants.

Abstract: The present invention generally relates to the modulation of hypoxia-inducible factor (HIF) using the compounds and methods disclosed herein. These compounds and methods can be applied to the prevention, pretreatment, and/or treatment of conditions or states associated with HIF, such as hypoxia- and ischemia-related conditions and the induction of stasis.

Abstract: The present invention relates to a method of treating hepatitis in a patient, which includes administering a pharmaceutical composition that includes carbon monoxide to the patient.

Abstract: In one aspect, the invention relates to compounds and methods useful for activating heme sensor systems; for decreasing virulence of bacteria, for example, Staphylococcus aureus; pharmaceutical compositions comprising the compounds; and methods of treating microbial-related disorders. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: The present invention relates to the treatment of disorders using heme oxygenase-1 and heme degradation products.

Abstract: The invention is to provide a gas mist pressure bath system, which is possible to control the amount of gas and liquid, pressure and others, and cause a gas mist to be absorbed through a skin and mucous membrane of a human living-body under an optimum condition, in which a mist is prepared by pulverizing and dissolving carbon dioxide or oxygen or a mixed gas of carbon dioxide and Oxygen and a liquid at a density of not less than a predetermined value, and the thus prepared gas mist is directly contacted to the skin and mucous membrane of the living-body, the gas mist pressure bath system comprises a gas supply, a liquid supply, a gas mist supply for generating and supplying the gas mist prepared by the liquid nozzle of pulverizing and dissolving the gas supplied from the gas supply as well as the liquid supplied from the liquid supply, and the living body cover member of covering the skin and mucous membrane of the living-body and forming a space of sealing the gas mist inside thereof, and the gas mist pressu

Abstract: The present invention provides for a method for treating an ischemic disorder in a subject which comprises administering to the subject a pharmaceutically acceptable form of a selectin antagonist in a sufficient amount over a sufficient time period to prevent white blood cell accumulation so as to treat the ischemic disorder in the subject. The invention further provides a method for treating an ischemic disorder in a subject which comprises administering to the subject carbon monoxide gas in a sufficient amount over a sufficient period of time thereby treating the ischemic disorder in the subject. The invention further provides a method for treating an ischemic disorder in a subject which comprises administering to the subject a pharmaceutically acceptable form of inactivated Factor IX in a sufficient amount over a sufficient period of time to inhibit coagulation so as to treat the ischemic disorder in the subject.

Abstract: The present invention is directed to dosing regimens for the administration of carbon monoxide in the treatment of various indications as well as methods for enhancing organ function following transplant thereof.

Abstract: In this disclosure, a method is described wherein the method comprises mixing a therapeutic gas or a therapeutic liquid or a combination thereof and a liquid carrier in a high shear device to produce a dispersion; and administering the produced dispersion intravenously to a patient; wherein the produced dispersion contains nanobubbles of the therapeutic gas or droplets of the therapeutic liquid with a mean diameter of less than about 1.5 ?m. In this disclosure, a system is also described wherein the system comprises a therapeutic gas source or a therapeutic liquid source or a combination thereof, a liquid carrier source; a high shear device (HSD) having an inlet, an outlet, at least one rotor, and at least one stator separated by a shear gap; and a pump configured to control the flow rate and residence time of a fluid passing through the high shear device.

Abstract: In this disclosure, methods and systems for drug delivery utilizing high shear are disclosed. In an embodiment, a method comprises (1) subjecting a therapeutic fluid containing a drug to high shear; and (2) obtaining a processed therapeutic fluid, wherein the processed therapeutic fluid contains the drug in nano-size. In an embodiment, a method comprises (1) subjecting a drug carrier and a therapeutic fluid containing a drug to high shear; and (2) obtaining a processed therapeutic fluid, wherein the processed therapeutic fluid contains the drug carrier loaded with the drug. In an embodiment, a method comprises (1) applying high shear to a drug carrier and a therapeutic fluid containing a drug; (2) obtaining a processed therapeutic fluid, wherein the processed therapeutic fluid contains the drug-loaded carrier; and (3) modifying the drug-loaded carrier with a targeting moiety to obtain a modified drug-loaded carrier.

Abstract: The present invention relates to a method of treating necrotizing enterocolitis in a patient, which includes administering a pharmaceutical composition that includes carbon monoxide to the patient.

Abstract: Several classes of in vivo carbon monoxide-releasing compounds are useful for the treatment and/or prevention of diseases, such as chronic inflammatory, e.g., rheumatoid arthritis, and of diseases with a strong inflammatory component, such as atherosclerosis, stroke, coronary disease, and Alzheimers disease. The in vivo carbon monoxide-releasing compounds can be attached to known drug vectors and/or known anti-inflammatory drugs, such as aspirin.

Abstract: The invention relates to solids made of a porous crystalline metal-organic framework (MOF) loaded with at least one gas of biological interest, and to a method for preparing the same. The MOF solids of the present invention are capable of adsorbing and releasing in a controlled manner gases having a biological interest. They can be used in the pharmaceutical field and/or for applications in the cosmetic field. They can also be used in the food industry.

Abstract: The invention relates to the use of carbon monoxide (CO) to inhibit the gastrointestinal side effects caused by non-steroidal anti-inflammatory drugs (NSAIDs) and/or alcohol.

Abstract: Methods for screening for agents that modulate the activation state, i.e., active growth or persistence, of Mycobacterium tuberculosis (Mtb), methods of treating an Mtb infection in a subject using agents identified by the screening methods, and methods for screening for a latent Mtb infection in a subject are disclosed. The screening methods involve contacting a Mtb sensor kinase with an agent to be tested, then detecting the response of the Mtb sensor kinase to modulating ligands or detecting changes in the oxidation state of the heme iron of the Mtb sensor kinase. The methods for treating an Mtb infection in a subject involve administering a therapeutically effective amount of an agent identified by the screening methods. The methods for screening for a latent Mtb infection in a subject involve detecting carbon monoxide or nitric oxide binding to heme iron of Mtb sensor kinases.

Abstract: This application relates to water-based personal moisturizers and lubricants that relive vaginal dryness. These compositions are non-spermicidal, sperm- and egg-friendly, and in various embodiments may mimic biological fluids, enhance sperm survival and motility, promote binding of sperm to eggs, and/or facilitate the process of fertilization. Related articles, systems, and methods of preparation and use of the compositions are also provided.

Abstract: The invention relates to the use of carbon monoxide (CO) to treat infections. The invention also provides novel carbon monoxide releasing molecules (CORMs).

Abstract: A method of making PVA microbubbles including a functionalisation step in which PVA polymeric chains are functionalised at their ends with aldehyde groups, and a subsequent cross-linking step, in which in an air-aqueous solution emulsion with a pH between 4.5 and 5.5 the previously functionalised PVA polymeric chains cross-link by means of an acetalisation reaction, thereby forming the microbubbles. The microbubbles produced are subsequently subjected to a lyophilising step, a filling step in which medicinal gas is introduced and a restoration step of the microbubbles by adding an aqueous solution.

Abstract: Methods and systems for isolating, assessing and treating lung compartments are disclosed. One or more lung compartments are accessed through an isolation catheter, oxygen rich gas is delivered to the compartments, and blood oxygen or exhaled carbon dioxide are monitored to assess lung compartment function. Diseased lung compartments may be treated using therapeutic agents delivered to the diseased compartments through the isolation catheter. Therapeutic agents include carbon monoxide, radioactive agents, chemotherapeutic agents or angiogenesis inhibitors and angiocidal agents.

Abstract: A device for providing improved wound healing is described. The device includes a vacuum system for applying a sub-atmospheric pressure to the wound, a gas supply system for applying a gaseous wound healing agent to the wound, and a controller connected with the vacuum system and the gas supply system that controls the applications of the sub-atmospheric pressure and the application of the gaseous wound healing agent to the wound. A method of using the device for improved wound healing is also described.

Abstract: The present invention relates to a method of treating patients suffering from, or at risk for, intimal hyperplasia and/or arteriosclerosis. The treatment includes administering a pharmaceutical composition that includes carbon monoxide to the patient.

Abstract: The present invention relates to a method of treating ileus in a patient, which includes administering a pharmaceutical composition that includes carbon monoxide to the patient.

Abstract: The present invention relates to the use of carbon monoxide (CO) as a biomarker and therapeutic agent of heart, lung, liver, spleen, brain, skin and kidney diseases and other conditions and disease states including, for example, asthma, emphysema, bronchitis, adult respiratory distress syndrome, sepsis, cystic fibrosis, pneumonia, interstitial lung diseases, idiopathic pulmonary diseases, other lung diseases including primary pulmonary hypertension, secondary pulmonary hypertension, cancers, including lung, larynx and throat cancer, arthritis, wound healing, Parkinson's disease, Alzheimer's disease, peripheral vascular disease and pulmonary vascular thrombotic diseases such as pulmonary embolism. CO may be used to provide anti-inflammatory relief in patients suffering from oxidative stress and other conditions especially including sepsis and septic shock.

Abstract: This invention provides articles of manufacture and bandages comprising compartments and layers comprising oxygen and other therapeutic gas storage forms and perfluorocarbons. This invention also provides for methods of delivering oxygen and other therapeutic gases to a tissue in a subject comprising a administering to the tissue a composition comprising a perfluorocarbon and a oxygen or therapeutic gas storage form, so as to thereby deliver oxygen or the therapeutic gas to the tissue.

Abstract: A method of treating a poison-caused pathology in an individual subject is described which includes administering a pharmaceutical composition including a therapeutically effective amount of a chloride current modulator, a therapeutically effective amount of an exogenous oxygen carrier, or a combination of a therapeutically effective amount of a chloride current modulator and a therapeutically effective amount of an exogenous oxygen carrier, to an individual subject exposed to a poison. Optionally, an inventive method further includes administering a therapeutic agent to inhibit poison-caused pathology. A composition according to the invention is described which includes a therapeutically effective amount of a chloride current modulator, a therapeutically effective amount of an exogenous oxygen carrier, or a combination of a therapeutically effective amount of a chloride current modulator and a therapeutically effective amount of an exogenous oxygen carrier.

Abstract: The present invention generally relates to the modulation of hypoxia-inducible factor (HIF) using the compounds and methods disclosed herein. These compounds and methods can be applied to the prevention, pretreatment, and/or treatment of conditions or states associated with HIF, such as hypoxia- and ischemia-related conditions and the induction of stasis.

Abstract: In order to provide a device and a method for increasing blood flow and an insulin-like growth factor with use of a large amount of carbonic gas nano bubbles, the device of the present invention includes: a bathtub 1; and a nano bubble-producing section 41 for producing carbonic gas nano bubbles in bath water in the bathtub 1.

Abstract: The present invention relates to compositions and methods for rendering medical devices less prone to fibrous encapsulation comprising the use of non-gaseous CO dissolved in a reservoir material. Upon exposure to a biological environment, non-gaseous CO is slowly desorbed and/or dissolved from the reservoir material which provides anti-fibrotic activity. These compositions and methods may be used directly on soft tissue implants and/or medical devices to treat and/or prevent conditions and disease states related to fibrosis. Furthermore, the compositions can be incorporated into materials that are used to create soft tissue implants and/or medical devices to imbue implants and devices with anti-fibrotic properties.

Abstract: The present invention relates to a method of treating patients suffering from, or at risk for, intimal hyperplasia and/or arteriosclerosis. The treatment includes administering a pharmaceutical composition that includes carbon monoxide to the patient.

Abstract: Several classes of in vivo carbon monoxide-releasing compounds are useful for the treatment and/or prevention of diseases, such as chronic inflammatory, e.g., rheumatoid arthritis, and of diseases with a strong inflammatory component, such as atherosclerosis, stroke, coronary disease, and Alzheimers disease. The in vivo carbon monoxide-releasing compounds can be attached to known drug vectors and/or known anti-inflammatory drugs, such as aspirin.

Abstract: The present invention relates to a method of treating cancer or unwanted angiogenesis in a patient, which includes administering a pharmaceutical composition that includes carbon monoxide to the patient.

Abstract: The present invention relates to methods and compositions of treating patients suffering from, or at risk for, hemorrhagic shock. The treatment includes administering to the patient a pharmaceutical composition that includes carbon monoxide.